Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saâda-Bouzid,C. Defaucheux,Andy Karabajakian,Virginia Palomar Coloma,Vincent Servois,Xavier Paoletti,Caroline Even,Jérôme Fayette,Joël Guigay,Delphine Loirat,Frederic Peyrade,Marie Alt,Jocelyn Gal,C. Le Tourneau,C. Le Tourneau +14 more
TLDR
Hyperprogression was observed in 29% of patients with R/M HNSCC treated with anti-PD-L1/PD-1 agents and correlated with a shorter progression-free survival (PFS), and mechanisms and causality of hyperprogression should further be assessed through prospective controlled studies.About:
This article is published in Annals of Oncology.The article was published on 2017-07-01 and is currently open access. It has received 443 citations till now. The article focuses on the topics: Head and neck squamous-cell carcinoma & Progression-free survival.read more
Citations
More filters
Journal ArticleDOI
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
TL;DR: This guide to cancer immunotherapy provides a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation.
Journal ArticleDOI
Head and neck squamous cell carcinoma
Daniel Johnson,Barbara Burtness,C. René Leemans,Vivian Wai Yan Lui,Julie E. Bauman,Jennifer R. Grandis +5 more
TL;DR: This Primer provides an overview of the epidemiology, pathogenesis and treatment of HNSCCs of different aetiologies and the effects of the cancer and its treatment on patient quality of life.
Journal ArticleDOI
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Sylvestre Le Moulec,L. Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Serge Koscielny,Stéphane Champiat,Charles Ferté,David Planchard,Jordi Remon,Marie Eve Boucher,Anas Gazzah,Julien Adam,Emilio Bria,Giampaolo Tortora,Jean-Charles Soria,Benjamin Besse,Benjamin Besse,Caroline Caramella +28 more
TL;DR: It is suggested that HPD is more common with PD-1/PD-L1 inhibitors compared with chemotherapy in pretreated patients with NSCLC and is also associated with high metastatic burden and poor prognosis in patients treated with PD.
Journal ArticleDOI
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E.W. Cohen,R. Bryan Bell,Carlo Bifulco,Barbara Burtness,Maura L. Gillison,Kevin J. Harrington,Quynh-Thu Le,Nancy Y. Lee,Rom Leidner,Rebecca L. Lewis,Lisa Licitra,Hisham Mehanna,Loren K. Mell,Adam Raben,Andrew G. Sikora,Ravindra Uppaluri,Fernanda Whitworth,Dan P. Zandberg,Robert L. Ferris +18 more
TL;DR: An expert committee formed by the Society for Immunotherapy of Cancer formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing serve as a foundation to assist clinicians’ understanding of the role of immunotherAPies.
Journal ArticleDOI
Novel patterns of response under immunotherapy.
Edith Borcoman,Yada Kanjanapan,Stéphane Champiat,Shumei Kato,Vincent Servois,Razelle Kurzrock,Sanjay Goel,Philippe L. Bedard,C. Le Tourneau,C. Le Tourneau +9 more
TL;DR: Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression, and the classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Related Papers (5)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris,George R. Blumenschein,Jérôme Fayette,Joël Guigay,A. Dimitrios Colevas,Lisa Licitra,Kevin J. Harrington,Stefan Kasper,Everett E. Vokes,Caroline Even,Francis P. Worden,Nabil F. Saba,Lara Carmen Iglesias Docampo,Robert I. Haddad,Tamara Rordorf,Naomi Kiyota,Makoto Tahara,Manish Monga,Mark Lynch,William J. Geese,Justin Kopit,James W. Shaw,Maura L. Gillison +22 more
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour,Jan Bogaerts,Andrea Marie Perrone,Robert Ford,Lawrence H. Schwartz,Lawrence H. Schwartz,Sumithra J. Mandrekar,Nan Lin,Saskia Litière,Janet Dancey,Alice P. Chen,F. Stephen Hodi,Patrick Therasse,Otto S. Hoekstra,Lalitha K. Shankar,Jedd D. Wolchok,Marcus Ballinger,Marcus Ballinger,Marcus Ballinger,Caroline Caramella,Elisabeth G.E. de Vries +20 more